Remifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor

Neuropharmacology

Volumn 73, Issue , 2013, Pages 368-379

  Nowoczyn, M ^a   Marie, N ^b,c,d   Coulbault, L ^a   Hervault, M ^a   Davis, A ^a   Hanouz, J L ^a   Allouche, S ^a  

^a France   (France)

^b CNRS   (France)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Analgesia; Desensitization; Morphine; Mu opioid receptor; Remifentanil; Tolerance

Indexed keywords

ADENYLATE CYCLASE; ARRESTIN 3; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; REMIFENTANIL; RETINA S ANTIGEN; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG CROSS TOLERANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

ANALGESIA; CFP; CYAN FLUORESCENT PROTEIN; DAMGO; DELTA-OPIOID RECEPTOR; DESENSITIZATION; DOP; ERK1/2; EXTRACELLULAR-REGULATED KINASE 1/2; G PROTEIN-COUPLED RECEPTOR; G PROTEIN-COUPLED RECEPTOR KINASE; GFP; GPCR; GREEN FLUORESCENT PROTEIN; GRK; MAP KINASE; MAXIMAL POSSIBLE EFFECT; MITOGEN-ACTIVATED PROTEIN KINASE; MOP; MORPHINE; MPE; MU-OPIOID RECEPTOR; NALTRINDOLE; NTI; REMIFENTANIL; TOLERANCE; [D-ALA(2),N-ME-PHE(4),GLY(5)-OL]-ENKEPHALIN; Β-FUNALTREXAMINE; ΒFNA;

ADENYLATE CYCLASE; ANALGESICS; ANIMALS; ARRESTINS; CELL LINE; CYCLIC AMP; DRUG TOLERANCE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MORPHINE; PHOSPHORYLATION; PIPERIDINES; PROTEIN TRANSPORT; RECEPTORS, OPIOID, MU;

EID: 84885139332     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.06.010     Document Type: Article

References (62)

1. Aguila, B., Coulbault, L, Boulouard, M., Léveillé, F., Davis, A., Tóth, G., et al, 2007. In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance. Br. J. Pharmacol. 152, 1312-1324.
2. Aguila, B., Coulbault, L., Davis, A., Marie, N., Hasbi, A., Le Bras, F., et al, 2012. ßarrestin1-biased agonism at human δ-opioid receptor by peptidic and alkaloid ligands. Cell. Signal. 24, 699-707.
3. Allouche, S., Hasbi, A., Ferey, V., Sola, B., Jauzac, P., Polastron, J., 2000. Pharmacological delta1- and delta2-opioid receptor subtypes in the human neuroblastoma cell line SK-N-BE: no evidence for distinct molecular entities. Biochem. Pharmacol. 59, 915-925.
4. Allouche, S., Polastron, J., Jauzac, P., 1996. The delta-opioid receptor regulates activity of ryanodine receptors in the human neuroblastoma cell line SK-N-BE. J. Neurochem. 67, 2461-2470.
5. Allouche, S., Roussel, M., Marie, N., Jauzac, P., 1999. Differential desensitization of human delta-opioid receptors by peptide and alkaloid agonists. Eur. J. Pharmacol. 371, 235-240.
6. Angst, M.S., Koppert, W., Pahl, I., Clark, DJ., Schmelz, M., 2003. Short-term infusion of the μ-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 106, 49-57.
7. Arttamangkul, S., Lau, E.K., Lu, H.-W., Williams, J.T., 2012. Desensitization and trafficking of μ-opioid receptors in locus ceruleus neurons: modulation by kinases. Mol. Pharmacol. 81, 348-355.
8. Avidor-Reiss, T., Bayewitch, M., Levy, R., Matus-Leibovitch, N., Nevo, I., Vogel, Z., 1995. Adenylylcyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. J. Biol. Chem. 270, 29732-29738.
9. Bailey, C.P., Oldfield, S., Llorente, J., Caunt, C.J., Teschemacher, A.G., Roberts, L, et al, 2009. Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br. J. Pharmacol. 158, 157-164.
10. Belcheva, M.M., Szücs, M., Wang, D., Sadee, W., Coscia, C.J., 2001. mu-Opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation. J. Biol. Chem. 276, 33847-33853.
11. Belcheva, M.M., Vogel, Z., Ignatova, E., Avidor-Reiss, T., Zippel, R., Levy, R., et al, 1998. Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J. Neurochem. 70, 635-645.
12. Bilecki, W, Zapart, G., Ligeza, A., Wawrzczak-Bargiela, A., Urbański, M.J., Przewłocki, R., 2005. Regulation of the extracellular signal-regulated kinases following acute and chronic opioid treatment. Cell. Mol. Life Sci. 62, 2369-2375.
13. Bohn, L.M., Gainetdinov, R.R., Lin, F.T., Lefkowitz, R.J., Caron, M.G., 2000. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 408, 720-723.
14. Cabañero, D., Campillo, A., Célérier, E., Romero, A., Puig, M.M., 2009a. Pronociceptive effects of remifentanil in a mouse model of postsurgical pain: effect of a second surgery. Anesthesiology 111, 1334-1345.
15. Cabañero, D., Célérier, E., García-Nogales, P., Mata, M., Roques, B.P., Maldonado, R., et al., 2009b. The pro-nociceptive effects of remifentanil or surgical injury in mice are associated with a decrease in delta-opioid receptor mRNA levels: prevention of the nociceptive response by on-site delivery of enkephalins. Pain 141, 88-96.
16. Choi, H.S., Kim, C.S., Hwang, CK., Song, K.Y., Wang, W, Qiu, Y., et al, 2006. The opioid ligand binding of human mu-opioid receptor is modulated by novel splice variants of the receptor. Biochem. Biophys. Res. Commun. 343, 1132-1140.
17. Cordonnier, L, Sanchez, M., Roques, B.P., Noble, F., 2007. Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments. Br. J. Pharmacol. 151, 75-83.
18. Cortínez, L.I., Brandes, V., Muñoz, H.R., Guerrero, M.E., Mur, M., 2001. No clinical evidence of acute opioid tolerance after remifentanil-based anaesthesia. Br. J. Anaesth. 87, 866-869.
19. Crawford, M.W., Hickey, C., Zaarour, C., Howard, A., Naser, B., 2006. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth. Analg. 102, 1662-1667.
20. Dang, V.C., Chieng, B., Azriel, Y., Christie, M.J., 2011. Cellular morphine tolerance produced by arrestin-2-dependent impairment of -opioid receptor resensitization. J. Neurosci. 31, 7122-7130.
21. Dershwitz, M., Randel, G.I., Rosow, C.E., Fragen, R.J., Connors, P.M., Librojo, E.S., et al, 1995. Initial clinical experience with remifentanil, a new opioid metabolized by esterases. Anesth. Analg. 81, 619-623.
22. Doll, C., Konietzko, J., Pöll, F., Koch, T., Höllt, V., Schulz, S., 2011. Agonist-selective patterns of m-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br. J. Pharmacol. 164, 298-307.
23. Eddy, N.B., Leimbach, D., 1953. Synthetic analgesics. II. Dithienylbutenyl- and dithienylbutylamines. J. Pharmacol. Exp. Ther. 107, 385-393.
24. Galandrin, S., Bouvier, M., 2006. Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy. Mol. Pharmacol. 70, 1575-1584.
25. Glass, P.S., Hardman, D., Kamiyama, Y., Quill, T.J., Marton, G., Donn, K.H., et al, 1993. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B). Anesth. Analg. 77, 1031-1040.
26. Groer, C.E., Schmid, C.L., Jaeger, A.M., Bohn, L.M., 2011. Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation. J. Biol. Chem. 286, 31731-31741.
27. Groer, C.E., Tidgewell, K., Moyer, R.A., Harding, W.W., Rothman, R.B., Prisinzano, T.E., et al, 2007. An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol. 71, 549-557.
28. Guignard, B., Bossard, A.E., Coste, C., Sessler, D.I., Lebrault, C., Alfonsi, P., et al, 2000. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology 93, 409-417.
29. Haberstock-Debic, H., Kim, K.-A., Yu, Y.J., Zastrow von, M., 2005. Morphine promotes rapid, arrestin-dependent endocytosis of mu-opioid receptors in striatal neurons. J. Neurosci. 25, 7847-7857.
30. Hayashida, M., Fukunaga, A., Hanaoka, K., 2003. Detection of acute tolerance to the analgesic and nonanalgesic effects of remifentanil infusion in a rabbit model. Anesth. Analg. 97, 1347-1352.
31. Horner, K., Zadina, J., 2004. Internalization and down-regulation of mu opioid receptors by endomorphins and morphine in SH-SY5Y human neuroblastoma cells. Brain Res. 1028, 121-132.
32. James, M.K., Feldman, P.L., Schuster, S.V., Bilotta, J.M., Brackeen, M.F., Leighton, H.J., 1991. Opioid receptor activity of GI 87084B, a novel ultra-short acting analgesic, in isolated tissues. J. Pharmacol. Exp. Ther. 259, 712-718.
33. Johnson, E.A., Oldfield, S., Braksator, E., González-Cuello, A., Couch, D., Hall, K.J., et al., 2006. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol. Pharmacol. 70, 676-685.
34. Joly, V., Richebe, P., Guignard, B., Fletcher, D., Maurette, P., Sessler, D.I., et al, 2005. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 103, 147-155.
35. Kenakin, T., 2011. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336, 296-302.
36. Koch, T., Höllt, V., 2008. Role of receptor internalization in opioid tolerance and dependence. Pharmacol. Ther. 117, 199-206.
37. 375 residues within the carboxyl tail differentially regulates mu-opioid receptor internalization. J. Biol. Chem. 276, 12774-12780.
38. 3H] noradrenaline release from SH-SY5Y cells. Biochem. Pharmacol. 46, 1145-1150.
39. Lecoq, I., Marie, N., Jauzac, P., Allouche, S., 2004. Different regulation of human delta-opioid receptors by SNC-80 [(+)-4-[(alphaR)-alpha- ((2S,5R)-4-allyl-2, 5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N, N-diethylbenzamide] and endogenous enkephalins. J. Pharmacol. Exp. Ther. 310, 666-677.
40. Levitt, E.S., Purington, L.C., Traynor, J.R., 2011. Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol. Pharmacol. 79, 461-471.
41. Liu, J.G., Ruckle, M.B., Prather, P.L., 2001. Constitutively active mu-opioid receptors inhibit adenylyl cyclase activity in intact cells and activate G-proteins differently than the agonist [D-Ala2, N-MePhe4, Gly-ol5]enkephalin. J. Biol. Chem. 276, 37779-37786.
42. Marie, N., Aguila, B., Allouche, S., 2006. Tracking the opioid receptors on the way of desensitization. Cell. Signal. 18, 1815-1833.
43. McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., et al, 2010. - Opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol. Pharmacol. 78, 756-766.
44. Melief, E.J., Miyatake, M., Bruchas, M.R., Chavkin, C., 2010. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc. Natl. Acad. Sci. U. S. A. 107, 11608-11613.
45. Noble, F., Szücs, M., Kieffer, B., Roques, B.P., 2000. Overexpression of dynamin is induced by chronic stimulation of mu- but not delta-opioid receptors: relationships with mu-related morphine dependence. Mol. Pharmacol. 58, 159-166.
46. Oakley, R.H., Laporte, S.A., Holt, J.A., Caron, M.G., Barak, L.S., 2000. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G proteincoupled receptors delineate two major classes of receptors. J. Biol. Chem. 275, 17201-17210.
47. Poisnel, G., Quentin, T., Barré, L., Coquerel, A., Debruyne, D., 2006. Competitive displacement binding assay on rat brain sections and using a beta-imager: application to mu-opioid ligands. J. Neurosci. Methods 154, 60-67.
48. Polastron, J., Mur, M., Mazarguil, H., Puget, A., Meunier, J.C., Jauzac, P., 1994. SK-N-BE: a human neuroblastoma cell line containing two subtypes of delta-opioid receptors. J. Neurochem. 62, 898-906.
49. Quillinan, N., Lau, E.K., Virk, M., Zastrow von, M., Williams, J.T., 2011. Recovery from mu-opioid receptor desensitization after chronic treatment with morphine and methadone. J. Neurosci. 31, 4434-4443.
50. Raynor, K., Kong, H., Chen, Y., Yasuda, K., Yu, L., Bell, G.I., et al, 1994. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol. Pharmacol. 45, 330-334.
51. Rivero, G., Llorente, J., McPherson, J., Cooke, A., Mundell, S.J., McArdle, C.A., et al, 2012. Endomorphin-2: a biased agonist at the μ-opioid receptor. Mol. Pharmacol. 82, 178-188.
52. Schulz, S., Mayer, D., Pfeiffer, M., Stumm, R., Koch, T., Höllt, V., 2004. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J. 23, 3282-3289.
53. Scott, L.J., Perry, C.M., 2005. Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs 65, 1793-1823.
54. 35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J. Pharmacol. Exp. Ther. 285, 496-505.
55. Spartà, A., Baiula, M., Campbell, G., Spampinato, S., 2010. beta-Arrestin 2-mediated heterologous desensitization of IGF-IR by prolonged exposure of SH-SY5Y neuroblastoma cells to a mu opioid agonist. FEBS Lett. 584, 3580-3586.
56. Trafton, J.A., Abbadie, C., Marek, K., Basbaum, A.I., 2000. Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation. J. Neurosci. 20, 8578-8584.
57. Vinik, H.R., Kissin, I., 1998. Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth. Analg. 86, 1307-1311.
58. Walwyn, W.M., Keith, D.E., Wei, W., Tan, A.M., Xie, C.W., Evans, C.J., et al, 2004. Functional coupling, desensitization and internalization of virally expressed mu opioid receptors in cultured dorsal root ganglion neurons from mu opioid receptor knockout mice. Neuroscience 123, 111-121.
59. Watts, V.J., 2002. Molecular mechanisms for heterologous sensitization of adenylate cyclase. J. Pharmacol. Exp. Ther. 302, 1-7.
60. Yu, Y., Zhang, L., Yin, X., Sun, H., Uhl, G.R., Wang, J.B., 1997. Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J. Biol. Chem. 272, 28869-28874.
61. Zaki, P.A., Keith, D.E., Brine, G.A., Carroll, F.I., Evans, C.J., 2000. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J. Pharmacol. Exp. Ther. 292, 1127-1134.
62. Zheng, H., Loh, H.H., Law, P.-Y., 2008. Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol. Pharmacol. 73, 178-190.